

Appl. No. 10/001,367  
Amdt. dated August 15, 2005  
Reply to Final Office Action of June 13, 2005

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A preparation comprising a homeopathic potency of purified insulin-like growth factor-1 (IGF-1) suitable for oral administration, wherein the concentration of said purified insulin-like growth factor-1 is less than  $1 \times 10^{-6}$  molar, and wherein said homeopathic potency is formulated in a liquid or solid formulation.

Claim 2 (previously presented): A preparation as recited in claim 1 additionally comprising at least one component selected from the group consisting of: a vitamin, a mineral, an amino acid, carnitine, CoQ10, vitamin K, vitamin E, Ginko Biloba, Phosphadityl Serine, an Omega 3 oil, flax seed, fish oil, polyamines, alpha hydroxy, glycolytic acid, and DHA.

Claim 3 (currently canceled): A preparation as recited in claim 1 in a liquid form for oral administration.

Claims 4 - 8 (canceled)

Claim 9 (previously presented): A preparation as recited in claim 1 wherein the homeopathic potency of IGF-1 is impregnated on a solid medium.

Claim 10 (previously presented): A preparation as recited in claim 1, wherein the purified insulin-like growth factor-1 is at least 95% pure.

Claim 11 (previously presented): A preparation as recited in claim 1, wherein the purified insulin-like growth factor-1 is a recombinant human protein.

Appl. No. 10/001,367  
Amdt. dated August 15, 2005  
Reply to Final Office Action of June 13, 2005

**Claim 12 (canceled)**

**Claim 13 (previously presented):** A preparation as recited in claim 1 wherein the purified insulin-like growth factor-1 has a homeopathic potency selected from the group consisting of: 6X, 6C, 15X, 12C, 30C, 100C, 200C, and 1M (1000C).

**Claim 14 (currently amended):** A preparation as recited in claim 1, additionally comprising a homeopathic potency of a substance selected from the group consisting of: a fibroblast growth factor (FGF), a platelet-derived growth factor (PDGF), an interleukin-1, an interleukin-2, and a hepatocyte growth factor.

**Claim 15 (previously presented):** A preparation as recited in claim 1 comprising a combination potency formulation having at least two homeopathic potencies.

**Claim 16 (previously presented):** A preparation as recited in claim 15, wherein the combination potency formulation comprises 6X and 12C homeopathic potencies.

**Claim 17 (previously presented):** A preparation as recited in claim 15, wherein the combination potency formulation comprises 6C, 100C, and 200C homeopathic potencies.

**Claim 18 (previously presented):** A preparation as recited in claim 15, wherein the combination potency formulation comprises 6C and 1M homeopathic potencies.

**Claim 19 (previously presented):** A preparation as recited in claim 1, additionally comprising one or more traditional homeopathics selected from the group consisting of: arsenicum, pulseatilla, aconite, hypericum, and metabolic sarcodes.

**Claim 20 (currently amended):** A preparation as recited in claim 1, further comprising a homeopathic preparation potency of purified growth hormone.

Appl. No. 10/001,367  
Amdt. dated August 15, 2005  
Reply to Final Office Action of June 13, 2005

Claim 21 (previously presented): A preparation as recited in claim 1, wherein the homeopathic potency of IGF-1 is 30C.

Claim 22 (previously presented): A preparation as recited in claim 1, wherein the homeopathic potency of IGF-1 is 1M.

Claim 23 (previously presented): A preparation as recited in claim 1, wherein the homeopathic potency of IGF-1 is 6C.

Claim 24 (currently amended): A preparation as recited in claim 1, comprising a homeopathic potency of purified insulin-like growth factor-1 (IGF-1) suitable for oral administration, wherein the concentration of said purified insulin-like growth factor-1 is less than  $1 \times 10^{-6}$  molar, and the preparation additionally comprising comprises homeopathic potencies of PDGF and TGF<sub>β1</sub>.

Claim 25 (previously presented): A preparation as recited in claim 24, wherein the IGF-1, PDGF and TGF<sub>β1</sub> homeopathic potencies are formulated using human recombinant proteins.

Claim 26 (previously presented): A preparation as recited in claim 24, wherein the IGF-1, PDGF and TGF<sub>β1</sub> homeopathic potencies are all 30C + 1M potencies.

Claim 27 (currently amended): A preparation as recited in claim 1, additionally comprising a homeopathic potency of purified insulin-like growth factor-1 (IGF-1) suitable for oral administration, wherein the concentration of said purified insulin-like growth factor-1 is less than  $1 \times 10^{-6}$  molar, and the preparation additionally comprising comprises homeopathic potencies of GM-CSF, PDGF<sub>BB</sub> and TGF<sub>β1</sub>.

Claim 28 (previously presented): A preparation as recited in claim 27, wherein the IGF-1, GM-CSF, PDGF<sub>BB</sub> and TGF<sub>β1</sub> homeopathic potencies are formulated using human recombinant proteins.

Appl. No. 10/001,367  
Amdt. dated August 15, 2005  
Reply to Final Office Action of June 13, 2005

Claim 29 (currently amended): A preparation as recited in claim 3-1, wherein the liquid form is an aqueous solution.

Claim 30 (previously presented): A preparation as recited in claim 9, wherein the solid medium is a tablet.